Only a small retrospective study indicated that PD-1/PD-L1 inhibitor + nab-paclitaxel showed significantly longer OS and higher response than PD-1/PD-L1 inhibitor monotherapy in second-line and above therapy for NSCLC [13]. This evidence concerns the gene CD274 and non-small cell lung carcinoma.